US OptionsDetailed Quotes

STIM240920C7500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayTrading Aug 26 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Jaguar8
    Jaguar8
    Aug 12 06:15
    NEWS
    $Neuronetics (STIM.US)$
    Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
    Neuronetics (NASDAQ: STIM) and Greenbrook TMS (OTCMKTS: GBNHF) have announced a definitive agreement to merge in an all-stock transaction. The merger aims to create a vertically-integrated organization providing TMS therapy with significant scale. Key benefits include:
    1. Increased brand awareness for NeuroStar TMS
    2. More consistent delivery of best practices
    3. Enhanced benefits for all NeuroStar c...
    Trytosaveabit
    Trytosaveabit
    Jul 22 07:34
    Update
    $Neuronetics (STIM.US)$ Reuters· 1 min ago
    Neuronetics: Aetna Updated Tms Coverage to Include Adolescents Aged 15 and Older With
    Jaguar8
    Jaguar8
    Jun 13 07:32
    NEWS
    $Neuronetics (STIM.US)$
    NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
    Neuronetics announced its participation in the 12th Annual Clinical TMS Society (CTMSS) Meeting in London from June 13-15, 2024. They will present six posters and one oral presentation showcasing data from the NeuroStar TMS System. Highlights include early prediction of nonresponse in major depressive disorder, the impact of treatment timing, efficacy of accelerated TMS protocols, effect...
    Trytosaveabit
    Trytosaveabit
    May 15 06:35
    Update
    $Neuronetics (STIM.US)$ Neuronetics Announced That Humana Has Become The First Commercial Payer To Address TMS Therapy Coverage For Adolescents
    Jaguar8
    Jaguar8
    Apr 10 07:32
    $Neuronetics (STIM.US)$
    NEWS
    New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
    Neuronetics, Inc. (NASDAQ: STIM) announces significant clinical findings in Brain Stimulation journal regarding the predictive value of early symptom improvement in major depressive disorder (MDD) patients undergoing transcranial magnetic stimulation (TMS) treatment. Lack of early improvement does not predict final non-response status, emphasizing the importance of completing the full 36-...
Read more